Loading…
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
Laubach, Jacob P., Liu, Chia-Jen, Raje, Noopur S., Yee, Andrew J., Armand, Philippe, Schlossman, Robert L., Rosenblatt, Jacalyn, Hedlund, Jacquelyn, Martin, Michael, Reynolds, Craig, Shain, Kenneth H., Zackon, Ira, Stampleman, Laura, Henrick, Patrick, Rivotto, Bradley, Hornburg, Kalvis T.V., Dumke, Henry J., Chuma, Stacey, Savell, Alexandra, Handisides, Damian R., Kroll, Stew, Anderson, Kenneth C., Richardson, Paul G., Ghobrial, Irene M.
Published in Clinical cancer research (15.01.2019)
Published in Clinical cancer research (15.01.2019)
Get full text
Journal Article
Loading…
Model‐based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma
Cheng, Yiming, Xue, Yongjun, Chen, Lu, Masin, Mark, Maciag, Paulo, Peluso, Teresa, Zhou, Simon, Li, Yan
Published in British journal of clinical pharmacology (01.01.2023)
Published in British journal of clinical pharmacology (01.01.2023)
Get full text
Journal Article
Loading…
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial
Morschhauser, Franck, Fitoussi, Olivier, Haioun, Corinne, Thieblemont, Catherine, Quach, Hang, Delarue, Richard, Glaisner, Sylvie, Gabarre, Jean, Bosly, André, Lister, John, Li, Ju, Coiffier, Bertrand
Published in European journal of cancer (1990) (01.09.2013)
Published in European journal of cancer (1990) (01.09.2013)
Get full text
Journal Article
Loading…
Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma
Frigault, Matthew J., Bishop, Michael R., Rosenblatt, Jacalyn, O’Donnell, Elizabeth K., Raje, Noopur, Cook, Daniella, Yee, Andrew J., Logan, Emma, Avigan, David E., Jakubowiak, Andrzej, Shaw, Kit, Daley, Heather, Nikiforow, Sarah, Griffin, Faith, Cornwell, Christine, Shen, Angela, Heery, Christopher, Maus, Marcela V.
Published in Blood advances (14.03.2023)
Published in Blood advances (14.03.2023)
Get full text
Journal Article
Loading…
Mechanistic Insights into Immune Related Toxicities in Subjects with Relapsed/ Refractory Follicular Lymphoma Treated with Zandelisib
Kandathilparambil Sasi, Binu, Martindale, Stephen P., Shupe, Samantha J., Fernandes, Stacey M., Yadav, Saurabh, Machado, John-Hanson, Phillips, Tycel, Zelenetz, Andrew D., Brown, Jennifer R.
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
Loading…
A phase 1/2 study to evaluate the safety and efficacy of XNW5004, a selective EZH2 inhibitor, in subjects with relapsed/refractory non-Hodgkin lymphoma
Qiu, Lugui, Qi, Junyuan, Zheng, Weiwei, Qian, Zhengzi, Zhou, Ke-Shu, Cai, Qingqing, Zhong, Kaili, Jing, Hongmei, Wu, Jianqiu, Xing, Xiaojing, Cao, Yang, Zhang, Xi, Zhou, Dongmei, Yan, Xiaojing, Zhang, Zhiye, Liang, Xinquan, Su, Liping, Yu, Wenjuan, He, Hongming
Published in Journal of clinical oncology (01.06.2025)
Published in Journal of clinical oncology (01.06.2025)
Get full text
Journal Article
Loading…
Population‐based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma
Wu, Liviawati S., Su, Yaming, Li, Claire, Zhou, Wangda, Jackson, Carolyn C., Sun, Yu‐Nien, Zhou, Honghui
Published in Clinical and translational science (01.12.2022)
Published in Clinical and translational science (01.12.2022)
Get full text
Journal Article
Loading…
A First-in-Human Study of CT0590, a Triple Knock-out, Allogeneic CAR T-Cell Therapy Targeting BCMA and NKG2A, in Subjects with Relapsed/Refractory Multiple Myeloma
Fu, Chengcheng, Yan, Lingzhi, Yao, Weiqin, Shang, Jingjing, Jin, Song, Yan, Shuang, Tang, Fang, Zhu, Ziling, Wu, Depei, Li, Ying, Rajakumaraswamy, Nishanthan, Zheng, Wei, Jiang, Hua, Liao, Zhaohui, Li, Zonghai
Published in Blood (05.11.2024)
Published in Blood (05.11.2024)
Get full text
Journal Article
Loading…
Interim results from the ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies
Namburi, Swathi, Latif, Tahir, Oluwole, Olalekan O., Cross, Scott J., Simmons, Gary, Iragavarapu, Chaitanya, Hu, Bei, Jih, Gloria, Bullaughey, Kevin, Das, Poulomee A, Devlin, Elizabeth, Flowers, Kevin, Fountaine, Thomas, Koumenis, Iphigenia, Ramachandran, Indu, Rothman, Sarah, Trede, Nikolaus S, Yee, Stephanie, Moyo, Tamara Kay
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
Loading…
Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma
Frigault, Matthew, Rosenblatt, Jacalyn, Dhakal, Binod, Raje, Noopur, Cook, Daniella, Gaballa, Mahmoud R., Emmanuel-Alejandro, Estelle, Nissen, Danielle, Cornwell, Christine, Banerjee, Kamalika, Rotte, Anand, Heery, Christopher R., Avigan, David, Jakubowiak, Andrzej, Bishop, Michael R.
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
Loading…
MP16-03 N-803 PLUS BCG COMPLETE RESPONSE RATE IN NMIBC CIS SUBJECTS: BCG REFRACTORY, RELAPSED, CHECKPOINT FAILURE, AND CHEMOTHERAPY FAILURE; UPDATED RESULTS (QUILT 3.032)
Soon-Shiong, Patrick, Reddy, Sandeep, Chamie, Karim
Published in The Journal of urology (01.05.2024)
Published in The Journal of urology (01.05.2024)
Get full text
Journal Article
Loading…
A Phase 1, First-in-Human, Dose Escalation and Dose-Expansion Study of a BCMAxCD38xCD3 Targeting Trispecific Antibody ISB 2001 in Subjects with Relapsed/Refractory Multiple Myeloma
Sia, Hanlon, Menon, Vinu, Garton, Andrew, Wolff, Eileen, Shah, Tejas, Charpentier, Colleen, Duchesne, Dominique, Pihlgren, Maria, Koch-Olsen, Jeppe, Drake, Adam, Perro, Mario, Zhukovsky, Eugene, Pacaud, Lida, Konto, Cyril
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Loading…
A First-in-Human, Phase 1, Dose Escalation Study of Sgr-2921 As Monotherapy in Subjects with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
DiNardo, Courtney D., Strickland, Stephen Anthony, Skikne, Barry, Zeidan, Amer M., Traer, Elie, Carraway, Hetty E., Frankel, Stanley, Weiss, Daniel E, Wang, Jacky H, Pirie-Shepherd, Steven, Piccotti, Joseph, Wright, D. Hamish, Akinsanya, Karen
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Loading…
Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase II Study
Bennani, N. Nora, Atherton, Pamela, Steinert, Kimberly O, Rimsza, Lisa M., Tun, Aung M., Hoffmann, Marc S., Narkhede, Mayur S., Vaidya, Rakhee, Said, Rabih, Shapiro, Geoffrey I, Costello, Brian A, Ansell, Stephen M, Nowakowski, Grzegorz S.
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Loading…
Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone
Li, Yan, Kassir, Nastya, Wang, Xiaomin, Palmisano, Maria, Zhou, Simon
Published in Journal of clinical pharmacology (01.08.2020)
Published in Journal of clinical pharmacology (01.08.2020)
Get more information
Journal Article
Loading…
A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001) and Orthogonal IL-2 (STK-009) in Subjects with Relapsed or Refractory CD19 Expressing Hematologic Malignancies (NCT05665062)
Palomba, Maria Lia, Caimi, Paolo F., Mei, Matthew, Hernandez-Ilizaliturri, Francisco, Shouse, Geoffrey, Winter, Allison M., Yedinak, Greg, Mou, David, Huang, Nestor, Moua, Anna, Oft, Martin, Aspuria, Paul-Joseph, Mehta-Damani, Anita, Rizvi, Naiyer, Unabia, Sherry, Taylor, Peg, McLeroy, Jeffrey, Cortese, Matthew J
Published in Blood (05.11.2024)
Published in Blood (05.11.2024)
Get full text
Journal Article
Loading…
A Phase 1b, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and/or Refractory Multiple Myeloma
Walling, Jackie M., Matusow, Bernice, Nichols, Christine, Singh, Parmveer, Inokuchi, Kerry, Bollag, Gideon
Published in Blood (05.11.2024)
Published in Blood (05.11.2024)
Get full text
Journal Article
Loading…
Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma
Witzig, Thomas E., Sokol, Lubomir, Kim, Won Seog, de la Cruz Vicente, Fátima, Caballero, Dolores, Advani, Ranjana, de Oña, Raquel, Marin Niebla, Ana, Terol, María José, Eva, Domingo Domenech, Bendris, Nawal, Ahsan, Julie Mackey, Leoni, Mollie, Foss, Francine M.
Published in Blood (23.11.2021)
Published in Blood (23.11.2021)
Get full text
Journal Article
Loading…
The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies
Rothman, Sarah, Das, Poulomee A, Yee, Stephanie, Ramachandran, Indu, Koumenis, Iphigenia, Cook, Terry A, Yuan, Ying, Trede, Nikolaus S., Mattour, Ahmad Hatem
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
Loading…
Phase 1 and Dose Expansion Study of APR-246 in Combination with Ibrutinib or Venetoclax-Based Therapy in Subjects with TP53-Mutant Relapsed and/or Refractory Non-Hodgkin Lymphomas (NHL) Including Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
Thompson, Meghan C., Davids, Matthew S., Jain, Nitin, Soumerai, Jacob D., Ramakrishnan Geethakumari, Praveen, Gubits, Amy, Hickman, Denice, Wennborg, Anders, Attar, Eyal C., Abdel-Wahab, Omar, Mato, Anthony R.
Published in Blood (05.11.2020)
Published in Blood (05.11.2020)
Get full text
Journal Article